Peptide receptor radionuclide therapy alone or in combination with temozolomide plus/minus capecitabine in [¹⁸F]FDG-positive metastatic neuroendocrine tumors.

ABSTRACT:

Background

Recent data demonstrate that one possibility for increasing Peptide Receptor Radionuclide Therapy (PRRT) results lies in the combination of PRRT with chemotherapy. This study aimed to evaluate response and outcome in [¹⁸F]FDG-positive metastatic neuroendocrine tumor (mNET) patients treated with PRRT alone or in combination with temozolomide (TEM) plus/minus capecitabine (CAP).

Methods

All mNET patients presented with [¹⁸F]FDG-positive disease prior to treatment (or retreatment) with PRRT alone or in combination with chemotherapy were retrospectively included in this single-center study. Patients received [¹⁷⁷Lu]Lu-DOTATATE with an activity of 7.4 GBq alone or combined with TEM (200 mg/kg/5d) plus/minus CAP (1500 mg/kg/14d). Contras

SUBMITTER: di Santo G 

PROVIDER: S-EPMC12860813 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature